19 recruiting. 19 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Recruiting 19 |
| Phase 2 | 3 | Recruiting 3 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Ou Bai, MD/PHD | 200 | 2026-05-30 | 2026-03-25 |
| A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL HMPL-760, HMPL-760 Placebo, R-GemOx - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Hutchmed | 240 | 2026-03-20 | 2026-07-20 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-08-04 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma Xinlikang capsules, mimic capsules - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Recruiting | Sun Yat-sen University | 80 | 2025-09-11 | 2025-11-26 |
| A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma Purinostat Mesylate for Injection, Selinexor Tablets - Recurrent and Refractory Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 390 | 2025-07-18 | 2025-09-19 |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1046 | 2025-01-27 | 2026-10-21 |
| Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ifupinostat Hydrochloride for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | BeBetter Med Inc | 416 | 2025-01-06 | 2026-08-19 |
| Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma Dexrazoxane, Rituximab, Cyclophosphamide - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Stichting Hemato-Oncologie voor Volwassenen Nederland | 324 | 2024-08-15 | 2026-09-23 |
| The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide, zanubrutinib, rituximab and lenalidomide - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Ruijin Hospital | 100 | 2024-07-29 | 2024-08-05 |
| A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma Odronextamab, Rituximab, Cyclophosphamide - Diffuse Large B-cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 904 | 2023-12-13 | 2026-10-07 |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma R-miniCHOP + Acalabrutinib, R-miniCHOP - Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Universität des Saarlandes | 330 | 2023-06-07 | 2026-06-29 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Zilovertamab vedotin, Rituximab, Gemcitabine - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 290 | 2022-01-14 | 2026-10-21 |
| The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk Six Courses of R-CHOP Plus Two Courses of Rituximab, Four Courses of R-CHOP Plus Four Courses of Rituximab - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Ruijin Hospital | 640 | 2021-09-17 | 2026-05-11 |
| Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line Adapted physical activity - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Weprom | 186 | 2021-09-08 | 2021-10-08 |
| Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses - Diffuse Large B-Cell Lymphoma, Elderly Patients | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 430 | 2021-03-23 | 2022-08-26 |
| A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma R-pola-mini-CHP, R-mini-CHOP - DLBCL, Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Nordic Lymphoma Group | 300 | 2020-08-19 | 2024-09-19 |
| Study of Out of Specification for Tisagenlecleucel CTL019 - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Novartis Pharmaceuticals | 200 | 2019-11-21 | 2026-09-15 |
Recurrence (3) · Burkitt Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Cardiotoxicity (1) · Cytokine Release Syndrome (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Heart Failure (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms (19) · Neoplasms by Histologic Type (19) · Lymphoma (18) · Lymphoma, B-Cell (18) · Lymphoma, Non-Hodgkin (17) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · DNA Virus Infections (2) · Epstein-Barr Virus Infections (2)
Rituximab (8) · Gemcitabine (4) · Oxaliplatin (4) · Cyclophosphamide (3) · Doxorubicin (3) · Injections (3) · Prednisolone (3) · Vincristine (3) · Lenalidomide (2) · Prednisone (2) · BEBT-908 (1) · Bendamustine Hydrochloride (1) · Carboplatin (1) · Cholecalciferol (1) · Dexrazoxane (1)
Merck Sharp & Dohme LLC (2) · Ruijin Hospital (2) · BeBetter Med Inc (1) · Chengdu Zenitar Biomedical Technology Co., Ltd (1) · Fondazione Italiana Linfomi - ETS (1) · Health Institutes of Turkey (1) · Hutchmed (1) · Lyell Immunopharma, Inc. (1) · Nordic Lymphoma Group (1) · Novartis Pharmaceuticals (1) · Ou Bai, MD/PHD (1) · Regeneron Pharmaceuticals (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Sun Yat-sen University (1)
China (10) · Italy (5) · Australia (4) · France (4) · Turkey (Türkiye) (4) · United States (4) · Brazil (3) · Canada (3) · Chile (3) · Denmark (3) · Israel (3) · Japan (3) · Poland (3) · South Korea (3) · Thailand (3)
A. van Rhenen, MD (1) · Francesco Merli, Dott. (1) · Konstantinos Christofyllakis, MD MSc (1) · Mats Jerkeman (1) · Moritz Bewarder, MD, PD (1) · Ou Bai, PHD (1) · Weili Zhao (1) · Yuankai Shi, Phd (1)
2023 (1)